Adipose-derived stem cells decolonize skin *Staphylococcus aureus* by enhancing phagocytic activity of peripheral blood mononuclear cells in the atopic rats

Jaehee Lee¹, Leejin Park², Hyeyoung Kim¹, Bong-il Rho³, Rafael Taeho Han¹, Sewon Kim³, Hee Jin Kim⁴, Heung Sik Na¹,* and Seung Keun Back⁵,*

¹Neuroscience Research Institute and Department of Physiology, Korea University College of Medicine, Seoul 02841, ²Glovi Plastic Surgery, Seoul 06031, ³Department of Microbiology, Korea University College of Medicine, Seoul 02841, ⁴Division of Biological Science and Technology, Science and Technology College, Yonsei University Mirae Campus, Wonju 26493, ⁵Department of Biomedical Laboratory Science, College of Medical Science, Konyang University, Daejeon 35365, Korea

**ARTICLE INFO**

Received May 9, 2022
Revised June 16, 2022
Accepted June 16, 2022

*Correspondence
Heung Sik Na
E-mail: hsna@korea.ac.kr
Seung Keun Back
E-mail: skback@konyang.ac.kr

**Key Words**
Adipose-derived stem cells
Antimicrobial peptides
Atopic dermatitis
Phagocytosis
*Staphylococcus aureus*

**ABSTRACT**

*Staphylococcus aureus* (*S. aureus*) is known to induce apoptosis of host immune cells and impair phagocytic clearance, thereby being pivotal in the pathogenesis of atopic dermatitis (AD). Adipose-derived stem cells (ASCs) exert therapeutic effects against inflammatory and immune diseases. In the present study, we investigated whether systemic administration of ASCs restores the phagocytic activity of peripheral blood mononuclear cells (PBMCs) and decolonizes cutaneous *S. aureus* under AD conditions. AD was induced by injecting capsaicin into neonatal rat pups. ASCs were extracted from the subcutaneous adipose tissues of naïve rats and administered to AD rats once a week for a month. Systemic administration of ASCs ameliorated AD-like symptoms, such as dermatitis scores, serum IgE, IFN-γ/IL-4 cell ratio, and skin colonization by *S. aureus* in AD rats. Increased FasL mRNA and annexin V⁺/7-AAD⁺ cells in the PBMCs obtained from AD rats were drastically reversed when co-cultured with ASCs. In contrast, both PBMCs and CD163⁺ cells bearing fluorescent zymosan particles significantly increased in AD rats treated with ASCs. Additionally, the administration of ASCs led to an increase in the mRNA levels of antimicrobial peptides, such as cathelicidin and β-defensin, in the skin of AD rats. Our results demonstrate that systemic administration of ASCs led to decolonization of *S. aureus* by attenuating apoptosis of immune cells in addition to restoring phagocytic activity. This contributes to the improvement of skin conditions in AD rats. Therefore, administration of ASCs may be helpful in the treatment of patients with intractable AD.

**INTRODUCTION**

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritic eczematous skin lesions with repeated remission and relapse. It has become a major public health problem in modern industrialized countries owing to its high prevalence, intractability, and unknown etiologies [1]. AD is implicated in multiple factors, such as bacterial infections, impaired skin barrier function, alteration of the immune system, and genetic background.

*Staphylococcus aureus* (*S. aureus*) has long been recognized as a key player in the pathogenesis of AD because it is observed to be colonizing the skin of patients with severe AD. Previous studies have shown that apoptotic cell death followed by colonization by *S. aureus* is common and plays a pivotal role in the development or aggravation of AD [2]. Many virulence factors in *S. aureus* induce
apoptosis in various cell types, including keratinocytes and immune cells [3]. Apoptotic cell death of the host immune cells may accelerate infection by pathogenic staphylococci [4]. Under physiological conditions, apoptosis and subsequent phagocytic clearance are immunologically silent. However, dysregulated apoptosis can stimulate abnormal immune responses such as cytokine production and T lymphocyte differentiation [5,6]. Given that the phagocytic activities of immune cells were significantly impaired in the AD patients along with apoptotic cell death and/or improper clearance of apoptotic cells in the skin, skin colonization by S. aureus, may be implicated in the pathogenesis of inflammatory skin diseases.

Adipose-derived stem cells (ASCs), the mesenchymal stem cells (MSCs) derived from adipose tissues, have been widely used not only for tissue regeneration and tissue engineering [7] but also in the treatment of various human diseases, such as myocardial infarction [8], liver disease [9], ischemic brain injury [10], and muscular dystrophy [11]. Moreover, ASCs have recently been considered as an attractive alternative therapy for a variety of immune-related human diseases because of their anti-inflammatory and immune-regulatory properties [12,13]. Administration of ASCs-culture medium or ASCs themselves has been reported to considerably improve AD and psoriasis [14,15]. The therapeutic effects of ASCs on inflammatory or allergic skin diseases are likely to involve the differentiation of keratinocytes [10], attenuation of Th2 inflammation [12], and regulation of B lymphocytes [15]. However, it is not yet clear whether ASCs affect apoptosis and phagocytic activities of host immune cells.

In the present study, we investigated whether cutaneous infection by S. aureus affects both apoptosis and phagocytic activity of peripheral blood mononuclear cells (PBMC) and whether ASCs could reverse AD-related pathologies caused by S. aureus. Our data indicate that ASCs treatment not only prevents apoptotic cell death of PBMCs but also enhances the phagocytic activities of PBMCs in AD conditions. In addition, our results show that ASCs treatment increases antimicrobial peptides (AMPs) in the skin; that can control S. aureus pathogenesis.

### Evaluation of cutaneous lesions

Cutaneous lesions were carefully inspected and evaluated by scoring [17]. In brief, a lesion of 25 mm² was adopted as the unit size for the extent of skin lesions. The dermatitis score was calculated by summing up the score of all the lesions. The lesions were assessed according to their severity, as shown in Table 1.

### Cells and flow cytometric assay

Subcutaneous adipose tissue was obtained from 10-week aged naïve male rats. ASCs were isolated and expanded as previously described [18]. The tissues were washed several times with PBS and minced on ice, followed by incubation with an equal volume of 0.075% collagenase I at 37°C for 1 h. After centrifugation, pellet was suspended in 5% DMEM and passed through a 70 μm cell strainer. ASCs were cultured in 5% DMEM (Welgene, Gyeongsan, Korea) containing 100 μg/ml of streptomycin and 100 U/ml of penicillin, supplemented with 5% CO₂. ASCs at passage number 3 or 4 were used for the present study. ASCs (1 × 10⁶ cells/10 μl Hartman solution) were injected into AD rats via the retro-orbital sinus once a week for a month [19].

PBMCs were isolated from whole blood by density gradient centrifugation using HISTOPAQUE-1077 (density: 1.077 g/ml; Sigma). After centrifugation, a white cloudy layer was obtained. Cells were incubated with adequate antibodies such as anti-CD4 (BD Bioscience, San Jose, CA, USA), anti-IFN-γ (eBioscience), anti-IL-4 (eBioscience), anti-CD163 (GHI/61), or isotype controls (BioLegend, San Diego, CA, USA). Transwell assays were performed using fresh PBMCs obtained from AD and naïve animals. PBMCs (1 × 10⁶ cells) and cultured ASCs (1 × 10⁶ cells) were plated in the bottom and top chambers (0.4 μm; SPL, Pocheon, Korea) of a transwell, respectively, and then incubated for 24 h at 37°C in 5% CO₂.

All cells were counted using a BD FACSCalibur (BD Biosciences). Data were analyzed using FCS express software (ver. 5, De Nove Software, Pasadena, CA, USA).

### METHODS

#### Animal model

All experiments were approved by the Korea University of Medicine Animal Research Policies Committee (Korea-2017-0145). Newborn rat pups were injected with capsaicin (50 mg/kg, s.c.; Sigma-Aldrich, St. Louis, MO, USA) within 48 h of birth to induce AD [16]. All animals were raised in a room maintained under a 12 h light/dark cycle (light on at 07:00 h) at 22°C ± 25°C, with free access to food and water.

### Table 1. Severity index for skin lesions

| Region | Score | Skin condition                        |
|--------|-------|---------------------------------------|
| Face   | 0     | Normal                                |
|        | 1     | Wispy fur                             |
|        | 2     | Alopecia and flare                    |
|        | 3     | Bleeding or ulcerative lesion         |
| Ears   | 0     | Normal                                |
|        | 1     | Flare                                 |
|        | 2     | Bleeding                              |
|        | 3     | Loss of part of the ear               |
| Back   | 0     | Normal                                |
|        | 1     | Wispy fur                             |
|        | 2     | Alopecia and flare                    |
|        | 3     | Bleeding or ulcerative lesion         |

*Table 1. Severity index for skin lesions*
Adipose-derived stem cells ameliorate atopic dermatitis

Phagocytosis assay

As previously described [20,21], phagocytic activity was evaluated by flow cytometry using a pHrodo-conjugated zymosan A bioparticles Phagocytosis kit (Invitrogen, Life Technologies, Carlsbad, CA, USA), according to the manufacturer's instructions. PBMCs (1 x 10^6 cells) were incubated with zymosan A bioparticles (0.5 mg/ml) at 37°C in the incubator for 1–2 h and then washed twice with PBS. Data are represented as the fraction of cells bearing fluorescent zymosan A bioparticles (0.5 mg/ml) at 37°C in the incubator for 1–2 h and then washed twice with PBS. Data are represented as the fraction of cells bearing fluorescent zymosan A bioparticles to the total monocyte gate.

Evaluation of apoptosis

The apoptosis of PBMCs was assayed using annexin V/7-AAD staining [22]. PBMCs were incubated successively with annexin V-FITC and 7-AAD in the dark for 15 and 5 min, respectively. Annexin V^+/7-AAD^+ cells were counted by flow cytometry. Data are presented as percentages of total PBMCs.

Serological and histological analysis

Serum IgE levels were measured using enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions (CUSABIO, Wuhan, China). Rat skin obtained one week after the last ASC treatment, were fixed with 4% formalin and embedded in paraffin. Sections (5 μm in thickness) were prepared and subjected to hematoxylin and eosin (H&E), Gram, and immunofluorescent staining with anti-S. aureus (Abcam, Cambridge, UK).

Quantification of cutaneous S. aureus

Cutaneous S. aureus was cultured and evaluated, as previously described [17]. Skin samples (2 mm in diameter) were obtained via punching biopsy. The samples (each 30 mg) were homogenized in pure water (Welgene) and serially diluted by a factor of 10. The diluted sample (100 μl) was inoculated on HiCropme Agar Base (Sigma-Aldrich) plate and then incubated at 37°C for 24 h. The number of colonies were counted in duplicate and expressed as colony-forming units (CFU) per mg of skin sample. The logarithmic scale of the number of colonies was used for the statistical analysis.

Quantitative real-time PCR

PBMCs and skin samples were collected from 8-week old AD and ASC-treated rats. Total RNA was isolated according to the manufacturer’s instructions using TRIzol reagent (Thermo Fisher Scientific, Waltham, MA, USA). The purified total RNA was reverse-transcribed to cDNA using the Reverse Transcription System (Promega, Madison, WI, USA). For quantitative analysis, we used the following pairs of primers: GAPDH (F: ACTTTGGCCTCGTGGAAAGGG, R: ACATGGGGGTAGGAACACG), FasL (F: AACTCCGTGAGTTCAACACC, R: CCTCATGGTCACAAGCGCG), Cathelicidin (F: CCGGT-GATTCGAGCCCCAAG, R: TGATACGAGGCCCATCACA), and β-defensin (F: GGGTCCGTGGCATTCTCAAA, R: TCCTGCAACAGTTGGGCTTAT). The relative expression of each gene was calculated using the 2^ΔΔCT method and each group was normalized to naïve values.

Statistics

All data are presented as mean ± SEM. Student’s t-test and One-way ANOVA were used wherever appropriate for statistical analysis. Statistical significance was set at p < 0.05. All statistical analyses were performed using the Sigma Stat (ver. 3.5; Systat Software Inc., San Jose, CA, USA).

RESULTS

Systemic administration of ASCs ameliorates atopic dermatitis

We first investigated whether ASC administration could ameliorate inflammatory skin conditions in AD rats. As previously reported [16], capsaicin injection into rat pups led to pruritic eczematous skin lesions all around the body later in life, which were very similar to human AD symptoms (Fig. 1B). Four weeks after capsaicin treatment, the animals were classified into two groups; one group was subjected to the administration of ASCs for next 4 weeks named the AD + ASC group, and the other group was excluded from the injection of ASCs, named the AD group. Before the treatment of ASCs, there was no difference in dermatitis score between the groups (199 ± 15.43 and 203.72 ± 13.68 for both the AD and AD + ASC groups, respectively) (Fig. 1C). The AD group still suffered from severe AD-like symptoms until eight weeks, with a dermatitis score of 192.50 ± 19.74 (Fig. 1B, C). Serological and flow cytometric analyses showed higher serum IgE levels, lower IFN-γ/IL-4+ cell ratios, and many more CD163+ cells in the AD group than in the naïve or AD + ASC group, indicating the presence of Th2-driven inflammation (Fig. 1D–F, **p < 0.01, ***p < 0.001, one-way ANOVA). In the AD + ASC group, the skin condition significantly improved after ASC administration (Fig. 1B, C, ***p < 0.001, paired t-test). The dermatitis score was 99.50 ± 16.52, which was markedly lower than that of the AD group (**p < 0.001, t-test). Consistently, histological results showed an improvement in the skin condition, such as a less thickened epidermis and a decrease in immune cells in the dermis. The IFN-γ/IL-4+ cell ratio was higher in the AD + ASC group than that in the AD group (Fig. 1E, **p < 0.01, t-test). In addition, both serum IgE and CD163+ cells were significantly
decreased in the AD + ASC group, which was comparable to that in naïve animals (Fig. 1D, F). Our data indicated that the therapeutic effect of ASCs is strongly related to the attenuation of Th2-dominant chronic inflammation.

**Staphylococcus aureus increases apoptotic cell death of the PBMCs**

Consistent with our previous study [16], colonization by *S. aureus* was evident in the skin of AD rats. Clusters of Gram-positive coccus-shaped cells were widely found in the superficial layers of AD rat skin (Fig. 2B, D). However, in the skin of naïve rats, these *S. aureus*-like cells were rarely detectable (Fig. 2A, C). To investigate whether skin colonization by *S. aureus* affects apoptotic cell death, annexin V^+^/7-AAD^+^ cells among the gated PBMCs were counted using flow cytometric analysis. As shown in Fig. 2E, the population of Annexin V^+^/7-AAD^+^ cells drastically increased in the AD rats (29.27 ± 3.34%) compared to naïve animals (8.67 ± 3.64%) (**p < 0.002, t-test), indicating an increase in apoptotic cell death of the PBMCs.

**Staphylococcus aureus decreases phagocytic activity of PBMCs**

As illustrated in Fig. 2F, flow cytometric analysis showed that the fraction of PBMCs bearing fluorescent zymosan A bioparticles significantly reduced in the AD rats (6.40 ± 0.77%) compared to naïve animals (12.57 ± 1.46%) (**p < 0.001, t-test). Meanwhile, there was no difference in the number of CD163^+^ cells emitting fluorescent signals between AD and naïve animals (Fig. 2G), despite the increase in total CD163^+^ cells in AD rats (Fig. 1F). These results imply defects in the phagocytic activity of PBMCs in AD rats.
Adipose-derived stem cells ameliorate atopic dermatitis

Korean J Physiol Pharmacol 2022;26(4):287-295

www.kjpp.net

Next, we tested whether S. aureus-induced apoptosis of PBMCs was mediated by Fas/FasL signaling, and whether ASCs treatment could prevent this apoptosis using an in vitro transwell assay. As shown in Fig. 3A, Fasl mRNA expression was greatly increased in the PBMCs of AD rats (**p < 0.001 vs. naïve PBMCs, one-way ANOVA), implying the pathogenic role of S. aureus in Fas/FasL-dependent apoptosis of immune cells. However, in PBMCs co-cultured with ASCs, Fasl mRNA expression was significantly reversed (**p < 0.01 vs. AD PBMCs, one-way ANOVA), although it was still upregulated compared to naïve PBMCs. Consistently, the population of Annexin V^+/7-AAD^+ cells was much smaller in the co-culture of PBMCs with ASCs than in the monoculture of AD PBMCs alone (Fig. 3B, #p < 0.05, t-test). Co-culture with ASCs also increased the population of CD163^+ cells bearing fluorescent zymosan A particles (Fig. 3C, #p < 0.05, t-test).

\[ A \]

\[ B \]

\[ C \]

Fig. 3. Adipose-derived stem cells (ASCs) attenuates apoptotic cell death of the peripheral blood mononuclear cells (PBMCs) and restores phagocytic activity of CD163^+ cells when co-cultured with atopic dermatitis (AD) PBMCs. (A) Quantitative analyses for Fasl mRNA of the PBMCs. Naïve and AD refers to the monoculture of the PBMCs from the naïve and AD rats, respectively. AD + ASC represents the co-culture of AD PBMCs and ASCs. Upregulation of Fasl mRNA expression in the AD PBMCs is partially reversed by co-culture with ASCs. **p < 0.002, ***p < 0.001, one-way ANOVA. (B) Fractions of Annexin V^+/7-AAD^+ cells to the total PBMCs. #p < 0.05, t-test. (C) Populations of the CD163^+ cells bearing fluorescent zymosan A bioparticles inside the cells. AD, atopic dermatitis. **p < 0.01, ***p < 0.001, t-test.
Systemic administration of ASCs increases phagocytic activity of the PBMCs

Next, we tested whether systemic administration of ASCs could enhance the phagocytic or clearance activity of PBMCs. In the AD + ASC group, both the Annexin V⁺/7-AAD⁺ and CD163⁺ cells were entirely reduced compared to the AD group (***p < 0.01, ****p < 0.001, one-way ANOVA) (Figs. 4A and 1F). However, the population of PBMCs and CD163⁺ cells that emitted fluorescent signals significantly increased in the AD + ASC group (Fig. 4B, C, *p < 0.05, **p < 0.01, ***p < 0.001, one-way ANOVA), despite the decrease in the total number of CD163⁺ cells (Fig. 1F). Our data suggest that ASCs treatment enhances the phagocytic and clearance activities of PBMCs in rats with AD.

ASCs treatment reduces skin colonization by S. aureus

Both Gram-staining and immunofluorescent studies using a specific antibody against S. aureus demonstrated widespread colonization by S. aureus in the superficial layers of AD rat skin (Fig. 5). Gram-positive and immunofluorescence signals were mostly observed under the cornified layer of the skin and around the deep hair follicles (Fig. 5A, C). However, these signals were drastically reduced in the skin of AD rats treated with ASCs (Fig. 5B, D). Consistently, we observed that the number of colonies of S. aureus were significantly lower in AD + ASCs rats than in AD rats (Fig. 5E) (*p < 0.05, one-way ANOVA).

Next, we examined whether decolonization of S. aureus following ASC administration was associated with AMPs. As illustrated in Fig. 5F and G, cathelicidin and β-defensin mRNA were significantly upregulated in AD rats treated with ASCs compared to control AD rats (**p < 0.05, ****p < 0.001, t-test). These results suggest that the upregulation of AMPs after ASCs treatment may be related to the decolonization of S. aureus in the skin of AD rats.

DISCUSSION

S. aureus has long been recognized as an important player in the pathogenesis of AD; therefore, decolonization of S. aureus is considered essential in AD treatment [23]. Our results revealed that systemic administration of ASCs not only prevented apoptosis of PBMCs, but also enhanced the phagocytic activity of PBMCs in AD rats. In addition, we demonstrated that ASCs were competent enough to increase AMPs in the skin of AD rats. These effects of ASCs are likely to be partly responsible for the decolonization of S. aureus.

Accumulating evidence has demonstrated that cutaneous colonization and/or infection by S. aureus induces apoptotic cell death in patients with AD, which is pivotal for the development or aggravation of AD [3,24]. Dysregulated apoptosis is known to upset immune homeostasis by abnormal differentiation of immune cells and cytokine production [25,26], which makes the environment susceptible to the development of inflammatory skin diseases. Many virulence factors in S. aureus induce apoptotic cell death through various apoptotic processes [27]. Among these processes, the Fas/FasL signaling pathway is likely to be involved in S. aureus toxin-induced apoptosis of PBMCs [3,24]. FasL (CD95L or CD178), a type-II transmembrane glycoprotein belonging to the tumor necrosis factor (TNF) family, plays a key role in apoptotic cell death in target cells expressing Fas on the surface. A previous study reported that staphylococcal enterotoxin B increased Fas-mediated apoptosis of PBMCs obtained from patients with AD [24]. The authors also reported that FasL expression was significantly increased in peripheral monocytes of patients. Consistently, in the present study, we also observed increase in FasL mRNA expression and apoptotic cell death in PBMCs of AD rats (Fig. 3A). However, in PBMCs co-cultured with ASCs, FasL mRNA expression and apoptotic cells were significantly reduced, although the underlying mechanisms are not suggested herein. It
has been also reported that Fas/FasL signals induce keratinocyte apoptosis [28] and skin inflammation that is independent of caspase activity [29], aggravating eczematous lesions in AD patients. It is noteworthy that pharmacological intervention in cell apoptosis, including interference of Fas/FasL interaction and some cytokines related to cell apoptosis, has therapeutic effects in murine models of S. aureus-induced sepsis [30].

Another important finding of the present study is that the systemic administration of ASCs enhances the phagocytic activity of PBMCs and M2 macrophages. The removal of apoptotic cells by phagocytes is important for maintaining tissue homeostasis, and the process is immunologically silent under physiological conditions [6]. Thus, it is not hard to imagine that defects in apoptotic cell clearance are closely linked to the development of many diseases, such as chronic inflammation and autoimmune diseases [6]. Conversely, the enhancement of phagocytosis is an attractive therapeutic method for these diseases. In the present study, using a phagocytic assay, we showed that the uptake of fluorescent zymosan bioparticles reduced significantly in the PBMCs of AD rats as compared to naïve healthy donors (Fig. 4B), indicating a reduction in phagocytic activity of these cells in AD conditions. Additionally, ASCs treatment drastically enhanced the phagocytic activity of both PBMCs and CD163⁺ cells. Consistent with our results, a recent clinical study also reported defects in the phagocytic activity of mononuclear cells obtained from patients with AD [31]. The authors of the clinical study suggested that excessive activation of the complement system is a possible cause. It is unclear how ASCs enhance the phagocytic activity of PBMCs and M2 macrophages. Several lines of evidence indicate that upregulation of anti-inflammatory cytokines, such as IL-10, following ASC treatment are related to the enhancement of phagocytic activity [32-34]. It has also been suggested that upregulation of CD206, an important scavenger receptor of M2 macrophages, enhances phagocytic activity in systemic lupus erythematosus [5]. However, it should be noted that unlike in autoimmune diseases such as systemic lupus erythematosus; MSCs prevent differentiation of CD163⁺ M2 macrophages in AD conditions characterized by Th2- and M2 macrophage-dominant inflammation [35]. In the present study, the systemic administration of ASCs reduced the total number of CD163⁺ cells in AD rats. However, many more CD163⁺ cells that had taken fluorescent zymosan bioparticles were counted in AD rats treated with ASCs, indicating functional enhancement of M2 macrophages. Han et al. [36] reported that M2 macrophages functionally activated by pharmacological intervention have therapeutic effects on AD in mice. Thus, ASCs treatment may be useful for restoring or enhancing the phago-
cytic activity of phagocytes. AMPs, also known as host defense peptides, are key components of the innate immune system that provide protection against invading pathogens [37]. In the human skin, nonpathogenic commensal bacteria and keratinocytes produce AMPs that inhibit colonization by pathogenic microbes. However, AMPs, especially cathelicidin (LL-37) and β-defensin, which have antimicrobial activities against S. aureus, are diminished in the human AD skin. Overexpression of Th2 cytokines, a hallmark of AD, has been known to be involved in the downregulation of AMPs [38,39]. Here, we showed that mRNA levels of cathelicidin and β-defensin were significantly increased in the skin of AD rats following systemic administration of ASCs. Cutaneous increases in AMPs might be correlated with skin decolonization of S. aureus and, therefore, improvement of skin conditions in AD rats.

The upregulation of AMPs seems to be associated with the role of ASCs in the differentiation of Th1 and Th2 cells, both of which are identified by their representative cytokines, INF-γ and IL-4, respectively. In the present study, we showed that ASCs treatment led to an increase in the IFN-γ/IL-4+ cell ratio, suggesting the alleviation of Th2 responses. Consistently, ASCs treatment reduced serum levels of IgE and the total number of CD163+ cells, both of which are upregulated by Th2 cytokines. A previous study demonstrated that topical application of ASCs-cultured medium promotes the production of AMPs in mouse skin [40]. ASCs are known to produce antimicrobial factors [41]. In conclusion, ASCs administration can help in decolonizing S. aureus from AD skin by upregulating AMPs.

S. aureus infection is a major challenge in the management of AD because of its diverse roles in the development or aggravation of the disease [2-4]. Many virulence factors of S. aureus, such as cytolytic toxins, exfoliative toxins, superantigens, destructive enzymes and protein A, are involved in skin inflammation and further immune dysregulation, causing a defective skin barrier [42]. In addition, cutaneous colonization of S. aureus reduces the diversity of the normal microflora of the skin that maintains immune homeostasis and prevents the growth of pathogens, making more susceptible environment for outgrowth of S. aureus [7,8,42]. Thus, decolonization may be essential for improving the clinical symptoms of AD.

In the present study, we showed that ASCs not only prevent apoptotic cell death of the PBMC but also enhance the phagocytic activities of PBMC with inhibiting Th2- and M2 macrophage-dominant inflammation in AD condition, contributing to decolonization of S. aureus in the skin. Antibiotics could be chosen for decolonizing S. aureus. However, it’s effectiveness is doubtful due to the occurrence of antibiotic resistance and bactericidal effects on beneficial normal flora, such as S. epidermidis and S. hominis. Therefore, the use of MSCs could be an alternative therapy for the decolonization of S. aureus.

**FUNDING**

This research was supported by a grant from Konyang University (2021A0057).

**ACKNOWLEDGEMENTS**

None.

**CONFLICTS OF INTEREST**

The authors declare no conflicts of interest.

**REFERENCES**

1. Leung DY, Bieber T. Atopic dermatitis. Lancet. 2003;361:151-160.
2. Kasraie S, Werfel T. Role of macrophages in the pathogenesis of atopic dermatitis. Mediators Inflamm. 2013;2013:942375.
3. Zhang X, Hu X, Rao X. Apoptosis induced by Staphylococcus aureus toxins. Microbiol Res. 2017;205:19-24.
4. Torchinsky MB, Garuda J, Blander JM. Infection and apoptosis as a combined inflammatory trigger. Curr Opin Immunol. 2010;22:55-62.
5. Deng W, Chen W, Zhang Z, Huang S, Kong W, Sun Y, Tang X, Yao G, Feng X, Chen W, Sun L. Mesenchymal stem cells promote CD206 expression and phagocytic activity of macrophages through IL-6 in systemic lupus erythematosus. Clin Immunol. 2015;161:209-216.
6. Poon IK, Lucas CD, Rossi AG, Ravichandran KS. Apoptotic cell clearance: basic biology and therapeutic potential. Nat Rev Immunol. 2014;14:166-180.
7. Zuz PA, Zhu M, Ashjian P, De Ugarte DA, Huang JL, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P, Hedrick MH. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002;13:4279-4295.
8. Valina C, Pinkernell K, Song YH, Bai X, Sadat S, Campeau RJ, Le Jemtel TH, Alt E. Intracoronary administration of autologous adipose tissue-derived stem cells improves left ventricular function, perfusion, and remodelling after acute myocardial infarction. Eur Heart J. 2007;28:2667-2677.
9. Harn HJ, Lin SZ, Hung SH, Subeq YM, Li YS, Syu WS, Ding DC, Lee RP, Hsieh DK, Lin PC, Chiou TW. Adipose-derived stem cells can abrogate chemical-induced liver fibrosis and facilitate recovery of liver function. Cell Transplant. 2012;21:2753-2764.
10. Lee EY, Xia Y, Kim WS, Kim MH, Kim TH, Kim KJ, Park BS, Sung JH. Hypoxia-enhanced wound-healing function of adipose-derived stem cells: increase in stem cell proliferation and up-regulation of VEGF and bFGF. Wound Repair Regen. 2009;17:540-547.
11. Alexeev V, Arita M, Donahue A, Bonaldo P, Chu ML, Igoucheva O. Human adipose-derived stem cell transplantation as a potential therapy for collagen VI-related congenital muscular dystrophy. Stem Cell Res Ther. 2014;5:21.
12. Gonzalez-Rey E, Gonzalez MA, Varela N, O’Valle F, Hernandez-
Cortes P, Rico L, Büscher D, Delgado M. Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Ann Rheum Dis. 2010;69:241-248.

13. González MA, Gonzalez-Rey E, Rico L, Büscher D, Delgado M. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology. 2009;136:978-989.

14. Yoon W, Jang S, Kook K. Use of adipose derived stem cells (ASCs) in treating autoimmune skin diseases: pilot study. Cytotherapy. 2016;18(6 Suppl):S132-S133.

15. Shin TH, Lee BC, Choi SW, Shin JH, Kang I, Lee JY, Kim JJ, Lee HK, Jung JE, Choi YW, Lee SH, Yoon JS, Choi JS, Lee CS, Seo Y, Kim HS, Kang KS. Human adipose tissue-derived mesenchymal stem cells alleviate atopic dermatitis via regulation of B lymphocyte maturation. Oncotarget. 2015;8:512-522.

16. Back SK, Jeong KY, Li C, Lee J, Lee SB, Na HS. Chronically relapsing pruritic dermatitis in the rats treated as neonate with capsaicin: a potential rat model of human atopic dermatitis. J Dermatol Sci. 2012;67:111-119.

17. Han RT, Kim HY, Ryu H, Jang W, Cha SH, Kim HY, Lee J, Back SK, Kim HJ, Na HS. Glyoxal-induced exacerbation of pruritus and dermatitis is associated with staphylococcus aureus colonization in the skin of a rat model of atopic dermatitis. J Dermatol Sci. 2018;90:276-283.

18. Bunnell BA, Flaat M, Gagliardi C, Patel B, Ripoll C. Adipose-derived stem cells: isolation, expansion and differentiation. Methods. 2008;45:115-120.

19. Yardeni T, Eckhaus M, Morris HD, Huizing M, Hoogstraten-Miller S. Retro-orbital injections in mice. Lab Anim (NY). 2011;40:155-160.

20. Lindner B, Burkard T, Schuler M. Phagocytosis assays with different pH-sensitive fluorescent particles and various readouts. Biotechniques. 2020;68:245-250.

21. Miksa M, Komura H, Wu R, Shah KG, Wang P. A novel method to determine the engulfment of apoptotic cells by macrophages using pHrodo succinimidyl ester. J Immunol Methods. 2009;342:71-77.

22. Lecoeur H, Ledru E, Prévost MC, Gougeon ML. Strategies for phenotyping apoptotic peripheral human lymphocytes comparing ISNT, annexin-V and 7-AAD cytofluorometric staining methods. J Immunol Methods. 1997;209:111-123.

23. Kuraitis D, Williams L. Decolonization of Staphylococcus aureus in healthcare: a dermatology perspective. J Healthc Eng. 2020;68:245-250.

24. Sohn MH, Kim JW, Won SK, Jang GC, Kim KE. Staphylococcal enterotoxin B upregulates Fas-mediated apoptosis of peripheral blood mononuclear cells in childhood atopic dermatitis. Scand J Immunol. 2003;57:62-67.

25. Aksid CA, Aksid M, Trautmann A, Blaser K. Immune regulation in atopic dermatitis. Curr Opin Immunol. 2000;12:641-646.

26. Yoshino T, Asada H, Sano S, Nakamura T, Imai S, Tamura M, Yoshikawa K. Impaired responses of peripheral blood mononuclear cells to staphylococcal superantigen in patients with severe atopic dermatitis: a role of T cell apoptosis. J Invest Dermatol. 2000;114:281-288.

27. Grassmé H, Jendrossek V, Gulbins E. Molecular mechanisms of bacteria induced apoptosis. Apoptosis. 2001;6:441-445.

28. Bien K, Zmigrodzka M, Orloški P, Fruba A, Szmyński L, Stankiewicz W, Nowak Z, Malewski T, Krzyżowska M. Involvement of Fas/ Fasl pathway in the murine model of atopic dermatitis. Inflamm Res. 2017;66:679-690.

29. Farley SM, Dotson AD, Purdy DE, Sundholm AJ, Schneider P, Magun BE, Iordanov MS. Fas ligand elicits a caspase-independent proinflammatory response in human keratinocytes: implications for dermatitis. J Invest Dermatol. 2006;126:2438-2451.

30. Bommhardt U, Chang KC, Swanson PE, Tinsley KW, Karl IE, Hotchkiss RS. Akt decreases lymphocyte apoptosis and improves survival in sepsis. J Immunol. 2004;172:7583-7591.

31. Abdullraheem YF, Alzolibani AA, Mahmoud KH, Korsani AH, Al-Harbi MH, Hassanin KM, Al-Dhubaibi MS. Clinical study and assessment of leukocyte phagocytic function in children with atopic dermatitis in Qassim region of Saudi Arabia. Int J Health Sci (Qassim). 2017;11:3-7.

32. Kim J, Hematti P. Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages. Exp Hematol. 2009;37:1445-1453.

33. Porcheray F, Vlaud S, Rimaniol AC, Léone C, Samah B, Dereuddre-Bosquet N, Dormont D, Gras G. Macrophage activation switching: an asset for the resolution of inflammation. Clin Exp Immunol. 2005;142:481-489.

34. Rösser T. Understanding the mysterious M2 macrophage through activation markers and effector mechanisms. Mediators Inflamm. 2015;2015:816460.

35. Yin X, Pang C, Bai L, Zhang Y, Geng L. [Adipose-derived stem cells promote the polarization from M1 macrophages to M2 macrophages]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2016;32:332-338. Chinese.

36. Han SC, Koo DH, Kang NJ, Yoon WJ, Kang GJ, Kang HK, Yoo ES. Docosahexaenoic acid alleviates atopic dermatitis by generating Tregs and IL-10/TGF-β-modified macrophages via a TGF-β-dependent mechanism. J Invest Dermatol. 2015;135:1556-1564.

37. Nguyen LT, Haney EF, Vogel HJ. The expanding scope of antimicrobial peptide structures and their modes of action. Trends Biotechnol. 2011;29:464-472.

38. Mallbrics L, Carlen L, Wei T, Heilborn J, Nilsson MF, Granath F, Ståhle M. Inhibitor downregulates the expression of the human cathelicidin protein hCAP18/LL-37 in atopic dermatitis. Exp Dermatol. 2010;19:442-449.

39. Nakatsuji T, Gallo RL. The role of the skin microbiome in atopic dermatitis. Ann Allergy Asthma Immunol. 2019;122:263-269. Erratum in: Ann Allergy Asthma Immunol. 2019;123:529.

40. Lee HJ, Jung M, Kim JH, Yoon YN, Choi EH. The effect of adipose-derived stem cell-cultured media on oxazolone treated atopic dermatitis. Cytotherapy. 2015;17:576-580.

41. Qian J, Hu Y, Zhao L, Xia J, Li C, Shi L, Xu F. Protective role of adipose-derived stem cell-educated cultured media on oxazolone treated atopic dermatitis-like murine model. Ann Dermatol. 2012;24:181-188.

42. Qian J, Hu Y, Zhao L, Xia J, Li C, Shi L, Xu F. Protective role of adipose-derived stem cells in Staphylococcus aureus-induced lung injury is mediated by RegIIIγ secretion. Stem Cells. 2016;34:1947-1956. Erratum in: Stem Cells. 2016;34:2798.

43. Geoghegan JA, Irvine AD, Foster TJ. Staphylococcus aureus and atopic dermatitis: a complex and evolving relationship. Trends Microbiol. 2018;26:484-497.